All In Biotech

Drug Trial Radar · NCT04167358

Linerixibat Long-term Safety, and Tolerability Study

Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Jul 8, 2020

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 \[NCT01899703\], 201000 GLIMMER \[NCT02966834\] (group 1) or 212620 GLISTEN \[NCT00210418\]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants. However, the total duration of study participation will vary by participant depending upon the time of entry relative to study end in their respective country.

Conditions

  • Cholestasis

Interventions

  • LinerixibatDrug

    All participants will receive linerixibat.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs)Time frame: Up to 66 months
  2. Number of participants with Severe AEsTime frame: Up to 66 months

Locations

94 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    West Hollywood, California

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Morrisville, North Carolina

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Capital Federal, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina

  • GSK Investigational Site

    Ciudad AutOnoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Santa Fe, Argentina

  • GSK Investigational Site

    Botucatu, Brazil

  • GSK Investigational Site

    Brasília, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Nanchang, China

  • GSK Investigational Site

    Nanjing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Tianjin, China

  • GSK Investigational Site

    Pilsen, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Erlangen, Germany

  • GSK Investigational Site

    Münster, Germany

  • GSK Investigational Site

    Haifa, Israel

  • GSK Investigational Site

    Holon, Israel

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.